

Expression of *IFITM1* in chronic myeloid leukemia patients

Cemaliye Boylu Akyerli^a, Meral Beksac^b, Michelle Holko^{c,d}, Mathias Frevel^c,
Klara Dalva^b, Uğur Özbek^e, Ender Soydan^b, Muhit Özcan^b, Gülsüm Özet^f,
Osman İlhan^b, Günhan Gürman^b, Hamdi Akan^b, Bryan R.G. Williams^c,
Tayfun Özçelik^{a,g,*}

^a Department of Molecular Biology and Genetics, Bilkent University, Bilkent, 06800 Ankara, Turkey

^b Department of Hematology, Ankara University School of Medicine, Sıhhiye, 06100 Ankara, Turkey

^c Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, 44195 OH, USA

^d Department of Genetics, Case Western Reserve University, Cleveland, 44106 OH, USA

^e Department of Genetics, Institute of Experimental Medicine, Istanbul University, 34280 Istanbul, Turkey

^f Division of Hematology, Numune Hospital, 06100 Sıhhiye, Ankara, Turkey

^g Ayhan Sahenk Foundation, 80670 Istanbul, Turkey

Received 4 March 2004; accepted 30 July 2004

Available online 18 October 2004

Abstract

We investigated the peripheral blood gene expression profile of interferon induced transmembrane protein 1 (*IFITM1*) in sixty chronic myeloid leukemia (CML) patients classified according to new prognostic score (NPS). *IFITM1* is a component of a multimeric complex involved in the transduction of antiproliferative and cell adhesion signals. Expression level of *IFITM1* was found significantly different between the high- and low-risk groups ($P = 9.7976 \times 10^{-11}$) by real-time reverse transcription polymerase chain reaction (RT-PCR). Higher *IFITM1* expression correlated with improved survival ($P = 0.01$). These results indicate that *IFITM1* expression profiling could be used for molecular classification of CML, which may also predict survival.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: Chronic myeloid leukemia; *IFITM1*; RT-PCR; Gene expression

1. Introduction

Chronic myeloid leukemia (CML) patients can be divided into three groups of low-risk, intermediate-risk, and high-risk, based on clinical parameters known as NPS [1]. Response of these risk groups to treatment is not uniform [2,3]. For example, low-risk patients respond better to interferon- α . Although CML was the first human disease in which a specific chromosomal abnormality [t(9; 22) (q34; q11)] could be linked to the pathogenic events of leukemogenesis [4,5], the gene expression profiles associated with each risk group remain unknown.

IFITM1, a component of a multimeric complex involved in the transduction of antiproliferative and cell adhesion signals [6], was suggested to play a role in the antiproliferative activity of interferons [7]. The sensitivity to inhibition of cell growth induced by interferons was found to correlate with the expression of this gene in various cell lines [8–10]. Furthermore, culture of human RSa cells with interferon- α resulted in increased resistance of the cells to cell killing by X-rays, and increased levels of *IFITM1* mRNA [11].

We hypothesized that *IFITM1* could be a molecular marker to identify patients in different CML risk groups based on the observations that this gene has a role in the antiproliferative activity of interferons, and low-risk CML patients respond better to interferon- α treatment. Therefore, we collected blood samples from 60 consecutive CML patients

* Corresponding author. Tel.: +90 312 290 2139; fax: +90 312 266 5097.
E-mail address: tozcelik@fen.bilkent.edu.tr (T. Özçelik).

classified according to NPS at initial diagnosis, analyzed *IFITM1* expression levels by real-time reverse transcription polymerase chain reaction (RT-PCR), and performed Kaplan-Meier analysis to correlate survival with *IFITM1* expression.

2. Materials and methods

2.1. Patients

Blood was obtained from high-risk ($n = 16$, NPS: 1484→3853), intermediate-risk ($n = 11$, NPS:784→1379), and low-risk ($n = 33$, NPS:21→708) CML patients, as well as four apparently healthy volunteers, following written informed consent. Patients ranged in age from 20 to 80 years old, with a mean age of 43.4 ± 13.2 (mean \pm S.D.), and a male to female ratio of 28–32 (Table 1). CML diagnosis was confirmed in all patients by in situ hybridization (Vysis Inc.) and by RT-PCR (Roche, Molecular Biochemicals) for BCR-ABL fusion. Regardless of risk group assignment, all patients received a short course of hydroxyurea followed by hydroxyurea or interferon during the median follow up duration of 26.5 months. Six patients who did not achieve remission with interferon based on BCR-ABL fusion analysis, received imatinib mesilate sequentially. Four patients (two low, one intermediate and one high-risk) received stem cell transplantation from siblings and are still alive.

2.2. RNA isolation

For gene expression analysis in CML it is important to include all types of leukocytes since CML involves cells from multiple hematopoietic lineages [4]. Therefore, RNA was isolated from the buffy coat. Consequently, our results represent gene expression from whole blood leukocytes. Total RNA was extracted with trizol (Invitrogen) and treated with DNaseI (DNA-free, Ambion) according to manufacturer's instructions [12]. Concentration and purity of the total RNAs were determined on the Beckman spectrophotometer Du640 (Beckman Instruments Inc.). All samples were run on denaturing agarose gel.

2.3. Real-time quantitative RT-PCR

The real-time RT-PCR assays were done with the iCycler instrument (BioRad Laboratories) using lightcycler-DNA master SYBR Green I (Roche, Molecular Biochemicals). The sequence of the primers used were: *IFITM1* F-5'-TGCACAAGG AGGAACATGAG-3'; *IFITM1* R-5'-CTGTTACAGAGCCGAATACC-3'. *GAPDH* was used as internal control (F-5'-GGCTGAGAACGGGAAGCTGTCAT-3' and R-5'-CAGCCTTCTCCATGGTGGTGAAGA-3'). Equal amounts of total RNA (3 μ g for each sample) were used in cDNA synthesis (RevertAid First Strand cDNA synthesis kit, MBI-Fermentas), and the quality of cDNA was initially tested by *GAPDH* RT-PCR amplification using 1/40 v

Table 1
Patient characteristics

Risk group/patient no.	Sex	Age	NPS	Disease phase
High ($n = 16$)				
CML-3	F	45	1511	Blastic
CML-7	F	22	3853	Blastic
CML-32	F	38	2550	Blastic
CML-45	M	56	1513	Blastic
CML-4	M	42	1968	Accelerated
CML-2	M	31	1495	Chronic
CML-10	F	50	1783	Chronic
CML-15	F	29	1484	Chronic
CML-23	M	28	1672	Chronic
CML-55	M	53	1604	Chronic
CML-58	F	52	1514	Chronic
CML-64	F	20	1518	Chronic
CML-71	M	50	1496	Chronic
CML-87	F	51	1511	Chronic
CML-89	M	55	1617	Chronic
CML-91	M	37	1498	Chronic
Low ($n = 33$)				
CML-6	M	24	142	Chronic
CML-8	M	35	584	Chronic
CML-12	F	52	708	Chronic
CML-13	M	40	578	Chronic
CML-14	F	46	383	Chronic
CML-17	M	63	708	Chronic
CML-18	F	25	41	Chronic
CML-22	M	36	635	Chronic
CML-25	F	43	259	Chronic
CML-29	M	36	259	Chronic
CML-31	F	47	21	Chronic
CML-46	F	39	21	Chronic
CML-51	F	38	25	Chronic
CML-54	F	42	141	Chronic
CML-56	M	46	112	Chronic
CML-59	F	32	204	Chronic
CML-60	F	65	667	Chronic
CML-62	M	35	497	Chronic
CML-65	F	47	204	Chronic
CML-68	F	37	210	Chronic
CML-69	M	24	550	Chronic
CML-70	F	58	667	Chronic
CML-74	F	23	141	Chronic
CML-75	F	34	214	Chronic
CML-78	M	49	164	Chronic
CML-79	F	26	21	Chronic
CML-80	F	33	42	Chronic
CML-81	M	38	217	Chronic
CML-82	F	25	105	Chronic
CML-83	M	51	708	Chronic
CML-84	F	43	576	Chronic
CML-85	F	47	259	Chronic
CML-86	M	29	284	Chronic
Intermediate ($n = 11$)				
CML-38	M	54	784	Blastic
CML-63	M	69	1017	Accelerated
CML-9	M	43	830	Chronic
CML-11	M	70	1025	Chronic
CML-19	F	51	1238	Chronic
CML-20	F	51	1310	Chronic
CML-28	M	57	1169	Chronic
CML-30	F	66	1379	Chronic
CML-43	M	42	1102	Chronic

Table 1 (Continued)

Risk group/patient no.	Sex	Age	NPS	Disease phase
CML-72	F	80	912	Chronic
CML-73	M	53	1080	Chronic

F: female; M: male; NPS: new prognostic score.

of cDNA. A pool of RNA from leukocytes of four healthy volunteers was used as control sample. The PCR reactions were set up in a volume of 20 μ l, containing 5 μ l of sample cDNA (1:5 dilution of the RT reaction in nuclease free water), 1 \times SYBR Green I dye, 1.5 mM MgCl₂, and 5 pmol from *IFITM1* and *GAPDH* specific primers. The cycling conditions were as follows: 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s for 45 cycles with initial melting at 95 °C for 5 min.

Relative expression levels were calculated using the PCR threshold cycle number (C_T) for each CML and control sample (both of which were normalized according to *GAPDH* mRNA for differences in amount of total RNA added to the reaction), using the formula $2^{-(\Delta C_{T\text{sample}} - \Delta C_{T\text{control}})}$ [13–15]. ΔC_T represents the difference in C_T values between the target and *GAPDH* transcripts. RT-PCR was performed in duplicates for each sample and average C_T values were calculated. Levels of gene transcripts between high- and low-risk CML were compared using Mann–Whitney *U*-test (Matlab 6 www.mathworks.com mannwhit matlab routine, <http://www.biol.ttu.edu/Strauss/Matlab/matlab.htm>) [16]. *P*-values <0.05 were considered statistically significant differences.

3. Results

3.1. Real-time RT-PCR results

We determined the relative transcript level of *IFITM1* in 60 CML patients by real-time RT-PCR analysis. The results showed that the relative transcript levels were significantly different between the high-risk (ranged between 0.0014 and 0.67; $n = 16$), and low-risk (1.2–6.1; $n = 33$) groups ($P = 9.7976 \times 10^{-11}$). The intermediate-risk group (0.8–5.2; $n = 11$) was similar to the low-risk group. The relative expression of *IFITM1* in different CML risk groups is shown in Fig. 1.

3.2. Kaplan–Meier analysis

We performed Kaplan–Meier analysis in all patients who have follow-up data for at least 26.5 months ($n = 24$). When patient survival was plotted according to *IFITM1* expression, independently of risk group assignment below or above the cutoff value of 1.0, the low-risk patients demonstrate higher levels of *IFITM1* expression compared to the high-risk patients. This finding significantly correlates with survival ($P = 0.01$; Fig. 2). Use of treatment drugs, hydroxyurea or interferon, were similar in all risk groups. Among the nine patients with the lowest *IFITM1* levels (<0.5), response to interferon was available in only two: both patients were resistant to interferon and imatinib mesilate.




Fig. 1. Relative expression of *IFITM1* by real-time RT-PCR in CML risk groups. Levels of gene transcripts between high- and low-risk CML were compared and found to be highly significant ($P = 9.7976 \times 10^{-11}$).




Fig. 2. Kaplan–Meier analysis: Kaplan–Meier plot of overall survival of patients according to *IFITM1* ($P = 0.01$) expression.

4. Discussion

Although gene expression profiles associated with CML have been reported [17,18], to the best of our knowledge, this is the first study in which *IFITM1* transcript levels at initial diagnosis are correlated with clinical parameters and survival. Currently, in the era of molecularly targeted therapies, use of interferon- α has been widely replaced by imatinib mesilate treatment. However, there are patients who do not respond to imatinib mesilate or develop resistance to it. These patients could be candidates for interferon administration or other treatment modalities. Thus a predictive test, which enables clinicians to select the most suitable treatment agent,

would be dramatically useful. Our results shows that the expression level of *IFITM1* is significantly different between the high- and low-risk groups ($P = 9.7976 \times 10^{-11}$), and higher *IFITM1* expression correlates with improved survival ($P = 0.01$). For example, high-risk CML patients who are expected to have a high proliferative capacity display decreased *IFITM1* expression. In an earlier study that was conducted by our group, *IFITM1* was found to be a differentially expressed transcript between two high-risk and two low-risk patients analyzed by cDNA microarrays [19]. Our results are also consistent with the previous observation that reports *IFITM1* in the control of cell growth by its antiproliferative activity [6]. Interestingly, interferon induced protein with tetratricopeptide repeats-2 (*IFIT2*) was found to be the most highly expressed gene during the chronic phase of CML [17]. These results suggest that higher expression of interferon induced genes in CML patients may serve as indicators of interferon- α sensitivity, which in turn may be used as molecular markers to predict response to interferon- α treatment.

IFITM1 expression levels do not appear to be directly correlated with the blast counts of the patients based on the real-time RT-PCR results. For example, the highest blast counts in low-risk patients were within a range of 5–8%, yet their *IFITM1* expression levels were higher than all of the high-risk patients including those with the lowest blast counts (4–8%).

The study reported here constitutes an initial attempt to identify candidate CML risk group indicator genes using expression profiling, and this profiling may lead to the development of a gene based classification system for CML which appears to be highly correlated with the clinical scoring at the time of initial diagnosis, and may predict disease outcome.

Acknowledgements

We thank the patients who took part in this study. This work was supported by grants from Bilkent University Research Fund, TÜBA, TÜBİTAK-SBAG-2513, and National Institutes of Health Grants R01-AI34093 and PO1-CA62220. C.B. Akyerli is a recipient of TÜBİTAK-BAYG NATO A2 fellowship. M. Beksac is a member of TÜBA (Turkish Academy of Sciences).

References

- [1] Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. *J Natl Cancer Inst* 1998;90:850–8.
- [2] Alimena G, Lazzarino M, Morra E, Mancini M, Cedrone M, Montefusco E, et al. Clinical and cytologic characteristics of blastic phase in Ph-positive chronic myeloid leukemia treated with α -interferon. *Leukemia* 1996;10:615–8.
- [3] Kloke O, Opalka B, Niederle N. Interferon alpha as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. *Leukemia* 2000;14:389–92.
- [4] Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. *New Engl J Med* 1999;341:164–72.
- [5] Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. *Blood* 2000;96:3343–56.
- [6] Deblandre GA, Marinx OP, Evans SS, Majaj S, Leo O, Caput D, et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. *J Biol Chem* 1995;270:23860–6.
- [7] Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. *Proc Natl Acad Sci USA* 1994;91:1198–205.
- [8] Knight Jr E, Fahey D, Blomstrom DC. Interferon-beta enhances the synthesis of a 20,000-dalton membrane protein: a correlation with the cessation of cell growth. *J Interferon Res* 1985;5:305–13.
- [9] Evans SS, Lee DB, Han T, Tomasi TB, Evans RL. Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemia B cells. *Blood* 1990;76:2583–93.
- [10] Evans SS, Collea RP, Leasure JA, Lee DB. IFN-alpha induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. *J Immunol* 1993;150:736–47.
- [11] Kita K, Sugaya S, Zhai L, Wu YP, Wano C, Chigira S, et al. Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by X-rays. *Radiat Res* 2003;160:302–8.
- [12] Frevel MAE, Bakheet T, Silva AM, Hissong JG, Khabar KSA, Williams BRG. p38 mitogen-activated protein kinase-dependent and independent signaling of mRNA stability of AU-rich element-containing transcripts. *Mol Cell Biol* 2003;23:425–36.
- [13] Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucl Acids Res* 2001;29:2002–7.
- [14] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C_T}$ method. *Methods* 2001;25:402–8.
- [15] Tanaka S, Kobayashi I, Utsuki S, Oka H, Fujii K, Watanabe T. O⁶-methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. *Int J Cancer* 2003;103:67–72.
- [16] Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. *Ann Math Stat* 1947;18:50–60.
- [17] Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. *Oncogene* 2001;20:8249–57.
- [18] Li H, Jie S, Zou P, Zou G. cDNA microarray analysis of chronic myeloid leukemia. *Int J Hematol* 2002;75:388–93.
- [19] Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Gürman G, et al. Analysis of high and low risk chronic myeloid leukemia by gene expression profiling. *Blood* 2002;100:365a (abstract).